John Grumitt, vice president of Diabetes UK and chief executive of Changing Health, says digital health innovators can work with big pharma to address medical needs.
Beckley Psytech, just months away from a readout of a phase 2b trial of its psychedelic therapy for treatment-resistant depression (TRD), has built anticipation with new d